Soligenix begins confirmatory phase 3 trial of HyBryte for treatment of cutaneous T-cell lymphoma: Princeton, New Jersey Wednesday, December 18, 2024, 14:00 Hrs [IST] Soligenix, I ...

Immutep (IMMP) announces favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating ...

Amai Proteins, a scale-up designer of novel proteins that answer the needs of consumers and industry, has succesfullly completed world's first double-blind, random clinical trial on the effects of ...

Viatris Inc. (VTRS) announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in ...

The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short ...

The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum ...

(NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light ...

For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart failure.

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response ...

The incidence of adverse events was similar among study groups (placebo = 84.6%, levetiracetam 2000 mg/day = 83.3%, levetiracetam 4000 mg/day = 84.2%) in the double-blind treatment period.

This was a randomised, double-blind, placebo-controlled ... were assessed at baseline and at the last assessment. A study sample size of 84 patients was calculated to provide 80% power with ...

Relying on a discredited 1998 study, he claims that “autism comes from vaccines ... He could order childhood vaccines, which ...